Akums Drugs and PharmaceuticalsNSE:AKUMS +4.05%39 ROA % is 6.21% as of Mar. 2026, which is 49% above its 10-year median of 4.17. GuruFocus rates NSE:AKUMS with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Akums Drugs and Pharmaceuticals ranks better than 62.69% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Akums Drugs and Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹3,385 Mil.
Akums Drugs and Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2026 was ₹54,470 Mil. Therefore, Akums Drugs and Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was 6.21%.
NSE:AKUMS'
s ROA % Range Over the Past 10 Years
Min: -9.65 Med: 4.17 Max: 8.86
Current: 5.2
During the past 6 years, Akums Drugs and Pharmaceuticals's highest ROA % was 8.86%. The lowest was -9.65%. And the median was 4.17%.
NSE:AKUMS's ROA % is ranked better than 62.69% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.74
vs NSE:AKUMS: 5.20
Akums Drugs and Pharmaceuticals (NSE:AKUMS) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Akums Drugs and Pharmaceuticals ROA % Related Terms
Akums Drugs and Pharmaceuticals ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akums Drugs and Pharmaceuticals ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's ROA % distribution charts can be found below:
* The bar in red indicates where Akums Drugs and Pharmaceuticals's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a ROA % of 6.21% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Akums Drugs and Pharmaceuticals and its competitors. This is 49% above median its historical median of 4.17. According to the industry distribution chart, Akums Drugs and Pharmaceuticals ranks #375 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 37.3%.
Is Akums Drugs and Pharmaceuticals' ROA % too high?
Akums Drugs and Pharmaceuticals' current ROA % of 6.21% is 49% above median its 10-year median of 4.17. The Drug Manufacturers industry median ROA % is 2.74. Akums Drugs and Pharmaceuticals' value of 6.21% is 126.6% above this industry median. Based on the distribution chart, Akums Drugs and Pharmaceuticals ranks #375 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Akums Drugs and Pharmaceuticals ranks #375 out of 1005 companies for ROA %. This puts Akums Drugs and Pharmaceuticals in the upper half of its industry. The industry median ROA % is 2.74. Akums Drugs and Pharmaceuticals' value of 6.21% is 126.6% above this benchmark. While the company's 10-year median is 4.17 vs. the industry median of 2.74, Akums Drugs and Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.74, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akums Drugs and Pharmaceuticals's current ROA % of 6.21% is 126.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Akums Drugs and Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akums Drugs and Pharmaceuticals's current ROA % is 6.21%, which is 49% above median its own 10-year median of 4.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current ROA % of 6.21%. The current ROA % is 6.21%, which is 49% above median its 10-year median of 4.17 and 126.6% above the Drug Manufacturers industry median of 2.74. Akums Drugs and Pharmaceuticals' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current ROA % is 6.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akums Drugs and Pharmaceuticals Business Description
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
39GF Score
Get the complete analysis for NSE:AKUMS
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AKUMS has been successfully added to your 
